CoChat

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

Lovera, JF, Frohman, E., Brown, TR, Bandari, D., Nguyen, L., Yadav, V., Stuve, O., Karman, J., Bogardus, K., Heimburger, G., Cua, L., Remingon, G., Fowler, J., Monahan, T., Kilcup, S., Courtney, Y., McAleenan, J., Butler, K., Wild, K., Whitham, R., Bourdette, D. · 2010 · Multiple Sclerosis Journal
Cited by 105

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer’s disease. Objective: Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI). Methods: This double-blind, randomized, placebo-controlled trial (Clinicaltrials.gov NCT00300716) compared memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose) with placebo. The primary outcome was the change from baseline to exit on the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall (LDFR). Secondary outcomes included additional neuropsychological tests; self-report measures of quality of life, fatigue, and depression; and family/caregiver reports of subjects’ CI and neuropsychiatric symptoms. Results: The differences between the groups on the change on the PASAT (placebo—memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) and on CVLT-II LDFR (placebo—memantine =—0.6 words, 95% CI —2.1, 0.8; p = 0.4) as well as on the other cognitive tests were not significant. Subjects on memantine had no serious adverse events (AEs) but had more fatigue and neurological AEs as well as, per family members’ reports, less cognitive improvement and greater neuropsychiatric symptoms than subjects on placebo. Conclusion: Memantine 10 mg twice a day does not improve CP in subjects with MS, ages 18—65, without major depression, who have subjective cognitive complaints and perform worse than one SD below the mean on the PASAT or on the California Verbal Learning Test-II (total recall or delayed free recall).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1352458510367662

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 105

Metadata

Authors
Lovera, J., Frohman, E., Brown, T., Bandari, D., Nguyen, L., Yadav, V., Stuve, O., Karman, J., Bogardus, K., Heimburger, G., Cua, L., Remingon, G., Fowler, J., Monahan, T., Kilcup, S., Courtney, Y., McAleenan, J., Butler, K., Wild, K., Whitham, R., & Bourdette, D.
Venue
Multiple Sclerosis Journal
Published
2010-05-18
Volume
16
Issue
6
Pages
715-723
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2066108884
Cited by
105
References
4
FWCI
7.50
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. https://app.cochat.ai/papers/10.1177/1352458510367662
The paper
Lovera, J., Frohman, E., Brown, T., Bandari, D., Nguyen, L., Yadav, V., Stuve, O., Karman, J., Bogardus, K., Heimburger, G., Cua, L., Remingon, G., Fowler, J., Monahan, T., Kilcup, S., Courtney, Y., McAleenan, J., Butler, K., Wild, K., . . . Bourdette, D. (2010). Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458510367662

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.